Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652483 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 433
- Enrollment target
NCT00652483: Completed Phase 3 study, sponsored by Allergan.
NCT00652483 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 433 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00652483, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 433 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
Interventions
- DRUG Brimonidine ophthalmic solution 0.1%
- DRUG Brimonidine ophthalmic solution 0.2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 433 participants |
| Start Date | 2003-05 |
| Est. Completion | 2004-09 |
| Phase | Phase 3 |
What the finished NCT00652483 record still lists
NCT00652483 is an interventional study that assigns participants to a tested intervention. The registered 433 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 2 interventions - of which Brimonidine ophthalmic solution 0.1% is the first listed.
NCT00652483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00652483 about?
NCT00652483 is a clinical study titled "Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension". This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
What is the current status of trial NCT00652483?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 433 participants. The study started on 2003-05. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00652483?
The interventions under investigation include: Brimonidine ophthalmic solution 0.1% (DRUG), Brimonidine ophthalmic solution 0.2% (DRUG).
Who is sponsoring clinical trial NCT00652483?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00652483's enrollment target sits among peer trials
433 876th of 2000 higher than 1,125 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743245 · 434 participants · NA
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
- NCT06471920 · 434 participants · NA
Improving Health for Patients With Chronic LBP in Rural Communities Through Telerehabilitation
- NCT07094113 · 434 participants · Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia